{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T06:30:30Z","timestamp":1791095430149,"version":"4.1.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>The combination of the CFTR (cystic fibrosis transmembrane conductance regulator) corrector lumacaftor with the potentiator ivacaftor has been approved for the treatment of patients with cystic fibrosis homozygous for the Phe508del CFTR mutation. The phase 3 trials examined clinical outcomes but did not evaluate CFTR function in patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To examine the effect of lumacaftor\u2013ivacaftor on biomarkers of CFTR function in Phe508del homozygous patients with cystic fibrosis aged 12 years and older.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective observational study assessed clinical outcomes including FEV1% predicted and body mass index, and CFTR biomarkers including sweat chloride concentration, nasal potential difference, and intestinal current measurement before and 8\u201316 weeks after initiation of lumacaftor\u2013ivacaftor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>A total of 53 patients were enrolled in the study, and 52 patients had baseline and follow-up measurements. After initiation of lumacaftor\u2013ivacaftor sweat chloride concentrations were reduced by 17.8 mmol\/L (interquartile range [IQR], \u221225.9 to \u22126.1; P\u2009&amp;lt;\u20090.001), nasal potential difference showed partial rescue of CFTR function in nasal epithelia to a level of 10.2% (IQR, 0.0\u201326.1; P\u2009&amp;lt;\u20090.011), and intestinal current measurement showed functional improvement in rectal epithelia to a level of 17.7% of normal (IQR, 10.8\u201329.0; P\u2009&amp;lt;\u20090.001). All patients improved in at least one CFTR biomarker, but no correlations were found between CFTR biomarker responses and clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Lumacaftor\u2013ivacaftor results in partial rescue of Phe508del CFTR function to levels comparable to the lower range of CFTR activity found in patients with residual function mutations. Functional improvement was detected even in the absence of short-term improvement of FEV1% predicted and body mass index.<\/jats:p>\n                    <jats:p>Clinical trial registered with www.clinicaltrials.gov (NCT02807415).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.201710-1983oc","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T10:49:00Z","timestamp":1515754140000},"page":"1433-1442","source":"Crossref","is-referenced-by-count":101,"title":["Effects of Lumacaftor\u2013Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis"],"prefix":"10.1093","volume":"197","author":[{"given":"Simon Y.","family":"Graeber","sequence":"first","affiliation":[{"name":"Department of Translational Pulmonology"},{"name":"Division of Pediatric Pulmonology and Allergy and Cystic Fibrosis Center, Department of Pediatrics, and"},{"name":"Translational Lung Research Center Heidelberg, German Center for Lung Research, University of Heidelberg, Heidelberg, Germany"},{"name":"Department of Pediatric Pulmonology and Immunology and Cystic Fibrosis Center, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Dopfer","sequence":"additional","affiliation":[{"name":"Clinic of Pediatric Pneumology, Allergology, and Neonatology and"},{"name":"Biomedical Research in Endstage and Obstructive Lung Disease Hannover, German Center for Lung Research, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Naehrlich","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Justus-Liebig-University Giessen, Giessen, Germany"},{"name":"Universities of Giessen and Marburg Lung Center, German Center for Lung Research, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Gyulumyan","sequence":"additional","affiliation":[{"name":"Clinic of Pediatric Pneumology, Allergology, and Neonatology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Scheuermann","sequence":"additional","affiliation":[{"name":"Department of Translational Pulmonology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Hirtz","sequence":"additional","affiliation":[{"name":"Department of Translational Pulmonology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Wege","sequence":"additional","affiliation":[{"name":"Department of Pneumology and Respiratory Critical Care Medicine, Thoraxklinik, University Hospital Heidelberg, Heidelberg, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heimo","family":"Mairb\u00e4url","sequence":"additional","affiliation":[{"name":"Translational Lung Research Center Heidelberg, German Center for Lung Research, University of Heidelberg, Heidelberg, Germany"},{"name":"Department of Pneumology and Respiratory Critical Care Medicine, Thoraxklinik, University Hospital Heidelberg, Heidelberg, Germany; and"},{"name":"Medical Clinic VII, Sports Medicine, Heidelberg University Hospital, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Dorda","sequence":"additional","affiliation":[{"name":"Clinic of Pediatric Pneumology, Allergology, and Neonatology and"},{"name":"Biomedical Research in Endstage and Obstructive Lung Disease Hannover, German Center for Lung Research, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Hyde","sequence":"additional","affiliation":[{"name":"Clinic of Pediatric Pneumology, Allergology, and Neonatology and"},{"name":"Biomedical Research in Endstage and Obstructive Lung Disease Hannover, German Center for Lung Research, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azadeh","family":"Bagheri-Hanson","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Justus-Liebig-University Giessen, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Rueckes-Nilges","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Justus-Liebig-University Giessen, Giessen, Germany"},{"name":"Universities of Giessen and Marburg Lung Center, German Center for Lung Research, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Fischer","sequence":"additional","affiliation":[{"name":"Clinic of Pediatric Pneumology, Allergology, and Neonatology and"},{"name":"Biomedical Research in Endstage and Obstructive Lung Disease Hannover, German Center for Lung Research, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus A.","family":"Mall","sequence":"additional","affiliation":[{"name":"Department of Translational Pulmonology"},{"name":"Division of Pediatric Pulmonology and Allergy and Cystic Fibrosis Center, Department of Pediatrics, and"},{"name":"Translational Lung Research Center Heidelberg, German Center for Lung Research, University of Heidelberg, Heidelberg, Germany"},{"name":"Department of Pediatric Pulmonology and Immunology and Cystic Fibrosis Center, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkhard","family":"T\u00fcmmler","sequence":"additional","affiliation":[{"name":"Clinic of Pediatric Pneumology, Allergology, and Neonatology and"},{"name":"Biomedical Research in Endstage and Obstructive Lung Disease Hannover, German Center for Lung Research, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,6,1]]},"reference":[{"key":"2026032023203616800_bib1","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"2026032023203616800_bib2","doi-asserted-by":"crossref","first-page":"15010","DOI":"10.1038\/nrdp.2015.10","article-title":"Cystic fibrosis","volume":"1","author":"Ratjen","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"2026032023203616800_bib3","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1183\/09031936.00228013","article-title":"CFTR: cystic fibrosis and beyond","volume":"44","author":"Mall","year":"2014","journal-title":"Eur Respir J"},{"key":"2026032023203616800_bib4","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor\u2013ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"key":"2026032023203616800_bib5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(16)30427-1","article-title":"Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study","volume":"5","author":"Konstan","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2026032023203616800_bib6","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S2213-2600(14)70132-8","article-title":"A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a Phe508del CFTR mutation: a phase 2 randomised controlled trial","volume":"2","author":"Boyle","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2026032023203616800_bib7","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S2213-2600(17)30215-1","article-title":"Efficacy and safety of lumacaftor and ivacaftor in patients aged 6\u201311 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial","volume":"5","author":"Ratjen","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2026032023203616800_bib8","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa0909825","article-title":"Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation","volume":"363","author":"Accurso","year":"2010","journal-title":"N Engl J Med"},{"key":"2026032023203616800_bib9","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1164\/rccm.201507-1271LE","article-title":"Intestinal current measurements detect activation of mutant CFTR in patients with cystic fibrosis with the G551D mutation treated with ivacaftor","volume":"192","author":"Graeber","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023203616800_bib10","first-page":"464","article-title":"[The German Center for Lung Research: translational research for the prevention, diagnosis and treatment of respiratory diseases] [article in German]","volume":"66","author":"Seeger","year":"2012","journal-title":"Pneumologie"},{"key":"2026032023203616800_bib11","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3\u201395-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J"},{"key":"2026032023203616800_bib12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"key":"2026032023203616800_bib13","article-title":"Sweat testing: sample collection and quantitative chloride analysis; approved guideline","volume-title":"CLSI document C34-A3","author":"Clinical and Laboratory Standards Institute","year":"2009","edition":"3rd ed"},{"key":"2026032023203616800_bib14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/978-1-61779-117-8_6","article-title":"Nasal potential difference measurements to assess CFTR ion channel activity","volume":"741","author":"Rowe","year":"2011","journal-title":"Methods Mol Biol"},{"key":"2026032023203616800_bib15","doi-asserted-by":"crossref","first-page":"e66955","DOI":"10.1371\/journal.pone.0066955","article-title":"Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation","volume":"8","author":"Rowe","year":"2013","journal-title":"PLoS One"},{"key":"2026032023203616800_bib16","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1164\/rccm.201003-0382OC","article-title":"Clinical phenotype and genotype of children with borderline sweat test and abnormal nasal epithelial chloride transport","volume":"182","author":"Sermet-Gaudelus","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023203616800_bib17","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1164\/rccm.201608-1754OC","article-title":"Lumacaftor\/ivacaftor in patients aged 6\u201311 years with cystic fibrosis and homozygous for F508del-CFTR","volume":"195","author":"Milla","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023203616800_bib18","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jcf.2017.04.011","article-title":"A multiple reader scoring system for nasal potential difference parameters","volume":"16","author":"Solomon","year":"2017","journal-title":"J Cyst Fibros"},{"key":"2026032023203616800_bib19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jcf.2013.09.007","article-title":"Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data","volume":"13","author":"Accurso","year":"2014","journal-title":"J Cyst Fibros"},{"key":"2026032023203616800_bib20","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1053\/j.gastro.2004.07.006","article-title":"CFTR Cl\u2013 channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis","volume":"127","author":"Hirtz","year":"2004","journal-title":"Gastroenterology"},{"key":"2026032023203616800_bib21","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1053\/gast.2000.8524","article-title":"Residual chloride secretion in intestinal tissue of \u0394F508 homozygous twins and siblings with cystic fibrosis","volume":"119","author":"Bronsveld","year":"2000","journal-title":"Gastroenterology"},{"key":"2026032023203616800_bib22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1053\/j.gastro.2003.10.049","article-title":"The \u0394F508 mutation results in loss of CFTR function and mature protein in native human colon","volume":"126","author":"Mall","year":"2004","journal-title":"Gastroenterology"},{"key":"2026032023203616800_bib23","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/0016-5085(91)90017-F","article-title":"Ion transport abnormalities in rectal suction biopsies from children with cystic fibrosis","volume":"101","author":"Veeze","year":"1991","journal-title":"Gastroenterology"},{"key":"2026032023203616800_bib24","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1172\/JCI0216112","article-title":"Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin\u2013induced intestinal fluid secretion","volume":"110","author":"Ma","year":"2002","journal-title":"J Clin Invest"},{"key":"2026032023203616800_bib25","doi-asserted-by":"crossref","first-page":"C231","DOI":"10.1152\/ajpcell.1999.276.1.C231","article-title":"Bumetanide blocks CFTR GCl in the native sweat duct","volume":"276","author":"Reddy","year":"1999","journal-title":"Am J Physiol"},{"key":"2026032023203616800_bib26","doi-asserted-by":"crossref","first-page":"e24445","DOI":"10.1371\/journal.pone.0024445","article-title":"The K+ channel opener 1-EBIO potentiates residual function of mutant CFTR in rectal biopsies from cystic fibrosis patients","volume":"6","author":"Roth","year":"2011","journal-title":"PLoS One"},{"key":"2026032023203616800_bib27","doi-asserted-by":"crossref","first-page":"e73905","DOI":"10.1371\/journal.pone.0073905","article-title":"Multicenter intestinal current measurements in rectal biopsies from CF and non-CF subjects to monitor CFTR function","volume":"8","author":"Clancy","year":"2013","journal-title":"PLoS One"},{"key":"2026032023203616800_bib28","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1164\/rccm.201606-1250PP","article-title":"Cystic fibrosis: the dawn of a new therapeutic era","volume":"195","author":"Heltshe","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023203616800_bib29","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1164\/rccm.201702-0266ED","article-title":"AJRCCM: 100-year anniversary: progress along the pathway of discovery leading to treatment and cure of cystic fibrosis","volume":"195","author":"Ramsey","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023203616800_bib30","doi-asserted-by":"crossref","first-page":"18843","DOI":"10.1073\/pnas.1105787108","article-title":"Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809","volume":"108","author":"Van Goor","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026032023203616800_bib31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/jmg.2007.053561","article-title":"Diversity of the basic defect of homozygous CFTR mutation genotypes in humans","volume":"45","author":"Stanke","year":"2008","journal-title":"J Med Genet"},{"key":"2026032023203616800_bib32","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1136\/thx.2009.125088","article-title":"Intestinal current measurement for diagnostic classification of patients with questionable cystic fibrosis: validation and reference data","volume":"65","author":"Derichs","year":"2010","journal-title":"Thorax"},{"key":"2026032023203616800_bib33","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1164\/rccm.200509-1377OC","article-title":"Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials","volume":"174","author":"Wilschanski","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023203616800_bib34","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1164\/rccm.201606-1107CI","article-title":"Early lung disease in infants and preschool children with cystic fibrosis: what have we learned and what should we do about it?","volume":"195","author":"Ranganathan","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023203616800_bib35","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1164\/rccm.201604-0893OC","article-title":"Comparison of lung clearance index and magnetic resonance imaging for assessment of lung disease in children with cystic fibrosis","volume":"195","author":"Stahl","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023203616800_bib36","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1164\/rccm.201610-2158OC","article-title":"Progression of lung disease in preschool patients with cystic fibrosis","volume":"195","author":"Stanojevic","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023203616800_bib37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jcf.2016.10.002","article-title":"Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor","volume":"16","author":"Fidler","year":"2017","journal-title":"J Cyst Fibros"},{"key":"2026032023203616800_bib38","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/thoraxjnl-2011-200393","article-title":"Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation","volume":"67","author":"Clancy","year":"2012","journal-title":"Thorax"},{"key":"2026032023203616800_bib39","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1172\/JCI5731","article-title":"\u0394F508 CFTR protein expression in tissues from patients with cystic fibrosis","volume":"103","author":"K\u00e4lin","year":"1999","journal-title":"J Clin Invest"},{"key":"2026032023203616800_bib40","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1091\/mbc.e04-11-1010","article-title":"Characterization of wild-type and \u0394F508 cystic fibrosis transmembrane regulator in human respiratory epithelia","volume":"16","author":"Kreda","year":"2005","journal-title":"Mol Biol Cell"},{"key":"2026032023203616800_bib41","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.bbadis.2010.08.001","article-title":"Functional analysis of F508del CFTR in native human colon","volume":"1802","author":"van Barneveld","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"2026032023203616800_bib42","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1164\/rccm.201603-0459OC","article-title":"Sources of variation in sweat chloride measurements in cystic fibrosis","volume":"194","author":"Collaco","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023203616800_bib43","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1164\/rccm.201404-0703OC","article-title":"Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis","volume":"190","author":"Rowe","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023203616800_bib44","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1164\/rccm.201609-1954OC","article-title":"Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections","volume":"195","author":"Hisert","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023203616800_bib45","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.chest.2017.10.005","article-title":"CORK study in cystic fibrosis: sustained improvements in ultra-low-dose chest CT scores after CFTR modulation with ivacaftor","volume":"153","author":"Ronan","year":"2018","journal-title":"Chest"},{"key":"2026032023203616800_bib46","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1172\/JCI12108","article-title":"Chloride conductance and genetic background modulate the cystic fibrosis phenotype of \u0394F508 homozygous twins and siblings","volume":"108","author":"Bronsveld","year":"2001","journal-title":"J Clin Invest"},{"key":"2026032023203616800_bib47","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"key":"2026032023203616800_bib48","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","article-title":"Tezacaftor\u2013ivacaftor in residual-function heterozygotes with cystic fibrosis","volume":"377","author":"Rowe","year":"2017","journal-title":"N Engl J Med"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/197\/11\/1433\/67148736\/ajrccm_197_11_1433.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/197\/11\/1433\/67148736\/ajrccm_197_11_1433.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T03:20:57Z","timestamp":1774063257000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/197\/11\/1433\/8498814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,1]]},"references-count":48,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,6,1]]},"published-print":{"date-parts":[[2018,6,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201710-1983oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,6]]},"published":{"date-parts":[[2018,6,1]]}}}